ALPHA BIO FRANCE : revenue, balance sheet and financial ratios

ALPHA BIO FRANCE is a French company founded 17 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in NEUILLY-SUR-MARNE (93330), this company of category PME shows in 2018 a revenue of 4.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - ALPHA BIO FRANCE (SIREN 507755890)
Indicator 2024 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C 4 756 411 € 4 665 407 € 4 407 093 €
Net income 2 129 706 € 1 602 696 € 1 931 196 € 969 006 € 1 243 224 € 904 347 € 859 677 € 957 940 €
EBITDA N/C N/C N/C N/C N/C 842 895 € 840 718 € 1 002 522 €
Net margin N/C N/C N/C N/C N/C 19.0% 18.4% 21.7%

Revenue and income statement

In 2024, ALPHA BIO FRANCE generates positive net income of 2.1 M€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 958 k€ -> 2.1 M€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

2 129 706 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 28%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 63%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

28.034%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

62.94%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

49.3%

Solvency indicators evolution
ALPHA BIO FRANCE

Sector positioning

Debt ratio
28.03 2024
2021
2022
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Average -10 pts over 3 years

In 2024, the debt ratio of ALPHA BIO FRANCE (28.03) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
62.94% 2024
2021
2022
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Excellent +25 pts over 3 years

In 2024, the financial autonomy of ALPHA BIO FRANCE (62.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 495.67. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

495.668

Liquidity indicators evolution
ALPHA BIO FRANCE

Sector positioning

Liquidity ratio
495.67 2024
2021
2022
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Excellent

In 2024, the liquidity ratio of ALPHA BIO FRANCE (495.67) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
ALPHA BIO FRANCE

Positioning of ALPHA BIO FRANCE in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of ALPHA BIO FRANCE is estimated at 1 749 586 € (range 665 905€ - 6 389 269€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
665k€ 1749k€ 6389k€
1 749 586 € Range: 665 905€ - 6 389 269€
NAF 5 all-time

Valuation method used

Net Income Multiple
2 129 706 € × 0.8x = 1 749 587 €
Range: 665 905€ - 6 389 269€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare ALPHA BIO FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about ALPHA BIO FRANCE

What is the revenue of ALPHA BIO FRANCE ?

The revenue of ALPHA BIO FRANCE in 2018 is 4.8 M€.

Is ALPHA BIO FRANCE profitable?

Yes, ALPHA BIO FRANCE generated a net profit of 2.1 M€ in 2024.

Where is the headquarters of ALPHA BIO FRANCE ?

The headquarters of ALPHA BIO FRANCE is located in NEUILLY-SUR-MARNE (93330), in the department Seine-Saint-Denis.

Where to find the tax return of ALPHA BIO FRANCE ?

The tax return of ALPHA BIO FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does ALPHA BIO FRANCE operate?

ALPHA BIO FRANCE operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.